Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2017, Article ID 3410946, 11 pages
https://doi.org/10.1155/2017/3410946
Review Article

Systematic Review and Critical Analysis of Cost Studies Associated with Parkinson’s Disease

1Programa de Pós-Graduação, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
2Movement Disorders Department in Neurology, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil
3Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil
4Neurology Program, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil

Correspondence should be addressed to Andre C. Felicio; moc.liamg@erdna.fc

Received 19 September 2016; Revised 24 January 2017; Accepted 12 February 2017; Published 5 March 2017

Academic Editor: Antonio Pisani

Copyright © 2017 Tânia M. Bovolenta et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Catalá-López, A. García-Altés, E. Alvarez-Martín, R. Gènova-Maleras, C. Morant-Ginestar, and A. Parada, “Burden of disease and economic evaluation of healthcare interventions: are we investigating what really matters?” BMC health services research, vol. 11, article 75, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. S.-Y. Liu, J.-J. Wu, J. Zhao et al., “Onset-related subtypes of Parkinson's disease differ in the patterns of striatal dopaminergic dysfunction: a positron emission tomography study,” Parkinsonism and Related Disorders, vol. 21, no. 12, pp. 1448–1453, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. X. Guo, W. Song, K. Chen et al., “Gender and onset age-related features of non-motor symptoms of patients with Parkinson's disease—a study from Southwest China,” Parkinsonism & Related Disorders, vol. 19, no. 11, pp. 961–965, 2013. View at Publisher · View at Google Scholar
  4. C. R. D. Nero, “What is health economics?” in Health Economics: Concepts and Contributions to Health Management, S. F. Piola and S. M. Vianna, Eds., chapter I, pp. 5–23, Ipea, Brasília, Brazil, 2002. View at Google Scholar
  5. T. Vanni, P. M. Luz, R. A. Ribeiro, H. M. D. Novaes, and C. A. Polanczyk, “Economic evaluation in health: applications in infectious diseases,” Cadernos de saúde pública, vol. 25, no. 12, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. Brazil Ministry of Health, Methodological Guidelines: Economic Evaluation of Health Technologies, Brazil Ministry of Health, Brasília, Brazil, 2009, http://bvsms.saude.gov.br/bvs/publicacoes/avaliacao_economica_tecnologias_saude_2009.pdf.
  7. E. Moraes, G. M. Campos, N. B. Figlie, R. R. Laranjeira, and M. B. Ferraz, “Introductory concepts of health economics and the social impact of alcohol abuse,” Revista Brasileira de Psiquiatria, vol. 28, no. 4, pp. 321–325, 2006. View at Publisher · View at Google Scholar
  8. S. R. Secoli, M. E. Nita, S. K. Ono-Nita, and M. Nobre, “Health technology assessment. II. Cost effectiveness analysis,” Arquivos de Gastroenterologia, vol. 47, no. 4, pp. 329–333, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. J.-E. Tarride, G. Blackhouse, M. Bischof et al., “Approaches for economic evaluations of health care technologies,” Journal of the American College of Radiology, vol. 6, no. 5, pp. 307–316, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Jo, “Cost-of-illness studies: concepts, scopes, and methods,” Clinical and Molecular Hepatology, vol. 20, no. 4, pp. 327–337, 2014. View at Publisher · View at Google Scholar
  11. D. P. Rice, “Cost of illness studies: what is good about them?” Injury Prevention, vol. 6, no. 3, pp. 177–179. View at Publisher · View at Google Scholar
  12. R. Tarricone, “Cost-of-illness analysis. What room in health economics?” Health Policy, vol. 77, no. 1, pp. 51–63, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Gustavsson, M. Svensson, F. Jacobi et al., “Cost of disorders of the brain in Europe 2010,” European Neuropsychopharmacology, vol. 21, no. 10, pp. 718–779, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. Organização Mundial da Saúde, Financing Health Systems: The Road to Universal Coverage, Organização Mundial da Saúde, Genebra, Switzerland, 2010, http://www.who.int/eportuguese/publications/WHR2010.pdf?ua=1.
  15. E. R. Dorsey, R. Constantinescu, J. P. Thompson et al., “Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030,” Neurology, vol. 68, no. 5, pp. 384–386, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. M. E. Morris, J. J. Watts, R. Iansek et al., “Quantifying the profile and progression of impairments, activity, participation, and quality of life in people with Parkinson disease: protocol for a prospective cohort study,” BMC Geriatrics, vol. 9, no. 1, article no. 2, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. M. T. Barbosa, P. Caramelli, D. P. Maia et al., “Parkinsonism and Parkinson's disease in the elderly: a community-based survey in Brazil (the Bambuí Study),” Movement Disorders, vol. 21, no. 6, pp. 800–808, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Andlin-Sobocki, B. Jönsson, H. U. Wittchen, and J. Olesen, “Cost of disorders of the brain in Europe,” European Journal of Neurology, vol. 12, supplement 1, pp. 1–27, 2005. View at Google Scholar · View at Scopus
  19. Y. J. Zhao, L. C. S. Tan, W. L. Au et al., “Estimating the lifetime economic burden of Parkinson's disease in Singapore,” European Journal of Neurology, vol. 20, no. 2, pp. 368–374, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Johnson, M. Davis, A. Kaltenboeck et al., “Early retirement and income loss in patients with early and advanced Parkinsons disease,” Applied Health Economics and Health Policy, vol. 9, no. 6, pp. 367–376, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Cubo, E. Alvarez, C. Morant et al., “Burden of disease related to Parkinson's disease in Spain in the year 2000,” Movement Disorders, vol. 20, no. 11, pp. 1481–1487, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. S. L. Kowal, T. M. Dall, R. Chakrabarti, M. V. Storm, and A. Jain, “The current and projected economic burden of Parkinson's disease in the United States,” Movement Disorders, vol. 28, no. 3, pp. 311–318, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Kaltenboeck, S. J. Johnson, M. R. Davis et al., “Direct costs and survival of medicare beneficiaries with early and advanced parkinson's disease,” Parkinsonism and Related Disorders, vol. 18, no. 4, pp. 321–326, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. D. M. Huse, K. Schulman, L. Orsini, J. Castelli-Haley, S. Kennedy, and G. Lenhart, “Burden of illness in Parkinson's disease,” Movement Disorders, vol. 20, no. 11, pp. 1449–1454, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Lökk, S. Borg, J. Svensson, U. Persson, and G. Ljunggren, “Drug and treatment costs in Parkinson's disease patients in Sweden,” Acta Neurologica Scandinavica, vol. 125, no. 2, pp. 142–147, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Jennum, M. Zoetmulder, L. Korbo, and J. Kjellberg, “The health-related, social, and economic consequences of parkinsonism: A Controlled National Study,” Journal of Neurology, vol. 258, no. 8, pp. 1497–1506, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Noyes, H. Liu, Y. Li, R. Holloway, and A. W. Dick, “Economic burden associated with Parkinson's disease on elderly Medicare beneficiaries,” Movement Disorders, vol. 21, no. 3, pp. 362–372, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. D. J. Cordato, R. Schwartz, E. Abbott, R. Saunders, and L. Morfis, “A comparison of health-care costs involved in treating people with and without Parkinson's disease in Southern Sydney, New South Wales, Australia,” Journal of Clinical Neuroscience, vol. 13, no. 6, pp. 655–658, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Bhattacharjee and U. Sambamoorthi, “Co-occurring chronic conditions and healthcare expenditures associated with Parkinson's disease: a propensity score matched analysis,” Parkinsonism and Related Disorders, vol. 19, no. 8, pp. 746–750, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. Y. Winter, S. Von Campenhausen, J. P. Reese et al., “Costs of Parkinson's disease and antiparkinsonian pharmacotherapy: an Italian cohort study,” Neurodegenerative Diseases, vol. 7, no. 6, pp. 365–372, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Vossius, M. Gjerstad, H. Baas, and J. P. Larsen, “Drug costs for patients with Parkinson's disease in two different European countries,” Acta Neurologica Scandinavica, vol. 113, no. 4, pp. 228–232, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. Winter, S. von Campenhausen, H. Brozova et al., “Costs of Parkinson's disease in Eastern Europe: a Czech cohort study,” Parkinsonism and Related Disorders, vol. 16, no. 1, pp. 51–56, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. P. McCrone, L. M. Allcock, and D. J. Burn, “Predicting the cost of Parkinson's disease,” Movement Disorders, vol. 22, no. 6, pp. 804–812, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. A. E. Spottke, M. Reuter, O. Machat et al., “Cost of illness and its predictors for Parkinson's disease in Germany,” PharmacoEconomics, vol. 23, no. 8, pp. 817–836, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. C. L. Leibson, K. Hall Long, D. M. Maraganore et al., “Direct medical costs associated with Parkinson's disease: a population-based study,” Movement Disorders, vol. 21, no. 11, pp. 1864–1871, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Ragothaman, S. T. Govindappa, R. Rattihalli, D. K. Subbakrishna, and U. B. Muthane, “Direct costs of managing Parkinson's disease in India: concerns in a developing country,” Movement Disorders, vol. 21, no. 10, pp. 1755–1758, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. Winter, S. V. Campenhausen, G. Popov et al., “Costs of illness in a Russian cohort of patients with parkinsons disease,” PharmacoEconomics, vol. 27, no. 7, pp. 571–584, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. J. Zhao, L. C. S. Tan, S. C. Li et al., “Economic burden of Parkinson's disease in Singapore,” European Journal of Neurology, vol. 18, no. 3, pp. 519–526, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. G. Tamás, L. Gulácsi, D. Bereczki et al., “Quality of life and costs in Parkinson's disease: a cross sectional study in Hungary,” PLoS ONE, vol. 9, no. 9, Article ID e107704, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Yoritaka, J. Fukae, T. Hatano, E. Oda, and N. Hattori, “The direct cost of Parkinson disease at Juntendo medical university hospital, Japan,” Internal Medicine, vol. 55, no. 2, pp. 113–119, 2016. View at Publisher · View at Google Scholar · View at Scopus
  41. S. J. Johnson, A. Kaltenboeck, M. Diener et al., “Costs of parkinson's disease in a privately insured population,” PharmacoEconomics, vol. 31, no. 9, pp. 799–806, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. A. P. Vargas, F. J. Carod-Artal, S. S. Nunes, and M. Melo, “Disability and use of healthcare resources in Brazilian patients with Parkinson's disease,” Disability and Rehabilitation, vol. 30, no. 14, pp. 1055–1062, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. J.-P. Bach, O. Riedel, J. Klotsche, A. Spottke, R. Dodel, and H.-U. Wittchen, “Impact of complications and comorbidities on treatment costs and health-related quality of life of patients with Parkinson's disease,” Journal of the Neurological Sciences, vol. 314, no. 1-2, pp. 41–47, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. P. Martínez-Martin, C. Rodriguez-Blazquez, S. Paz et al., “Parkinson symptoms and health related quality of life as predictors of costs: A Longitudinal Observational Study with Linear Mixed Model Analysis,” PLOS ONE, vol. 10, no. 12, Article ID e0145310, 2015. View at Publisher · View at Google Scholar · View at Scopus
  45. S. von Campenhausen, Y. Winter, A. Rodrigues e Silva et al., “Costs of illness and care in Parkinson's disease: an evaluation in six countries,” European Neuropsychopharmacology, vol. 21, no. 2, pp. 180–191, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. Y. Winter, M. Balzer-Geldsetzer, A. Spottke et al., “Longitudinal study of the socioeconomic burden of Parkinson's disease in Germany,” European Journal of Neurology, vol. 17, no. 9, pp. 1156–1163, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. Y. Winter, M. Balzer-Geldsetzer, S. von Campenhausen et al., “Trends in resource utilization for Parkinson's disease in Germany,” Journal of the Neurological Sciences, vol. 294, no. 1-2, pp. 18–22, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. G. Wang, Q. Cheng, R. Zheng et al., “Economic burden of Parkinson's disease in a developing country: a retrospective cost analysis in Shanghai, China,” Movement Disorders, vol. 21, no. 9, pp. 1439–1443, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. R. Dodel, B. Jönsson, J. P. Reese et al., “Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's disease,” Movement Disorders, vol. 29, no. 2, pp. 169–176, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Langer, “A framework for assessing Health Economic Evaluation (HEE) quality appraisal instruments,” BMC health services research, vol. 12, article no. 253, 2012. View at Publisher · View at Google Scholar · View at Scopus